纵向血浆代谢组学指导食管鳞状细胞癌化疗免疫治疗的动态风险评估与饮食调节
Longitudinal Plasma Metabolomics Guides Dynamic Risk Assessment and Dietary Modulation for Esophageal Squamous Cell Cancer Chemoimmunotherapy.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Discovery and validation of proliferative exhausted T cells as a favorable prognostic biomarker in esophageal squamous cell carcinoma.
Discovery and validation of proliferative exhausted T cells as a favorable prognostic biomarker in esophageal squamous cell carcinoma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
食管鳞状细胞癌(ESCC)是一种侵袭性恶性肿瘤,治疗手段有限且预后较差。尽管慢性抗原刺激下耗竭T细胞(Tex)的异质性已被认识,但Tex亚群在塑造肿瘤微环境(TME)和影响ESCC结局中的作用仍不清楚。
我们整合了单细胞RNA测序、TCR测序、微阵列和bulk RNA测序来解析Tex细胞。我们在发现队列和验证队列中鉴定出一个新的增殖性Tex(prolif Tex)亚群,其高浸润与患者生存改善显著相关。拟时序轨迹提示prolif Tex起源于Tex细胞,而TCR测序揭示了Tex与prolif Tex之间的克隆扩增和共享的受体库。新辅助化疗-免疫治疗降低了ESCC样本中prolif Tex的比例和分化潜能。利用prolif Tex亚群特异性基因开发了一个机器学习衍生的预后模型,并通过qRT-PCR使用本机构ESCC样本进行了验证。实验验证证实了候选基因在肿瘤与正常组织中的差异表达,其中高ESCO2表达与生存期延长相关。
我们的发现揭示了prolif Tex细胞是ESCC中一种新的TME亚群,其丰度预测有利的结局。基于prolif Tex的预后模型显示出强大的预后价值,且经验证的核心基因提供了潜在的生物标志物和治疗靶点。
我们的发现强调了prolif Tex细胞作为ESCC生物标志物和治疗靶点的潜力。
Esophageal squamous cell carcinoma (ESCC) is an aggressive malignancy with limited therapies and poor prognosis. While exhausted T cell (Tex) heterogeneity under chronic antigen stimulation is recognized, the role of Tex subsets in shaping the tumor microenvironment (TME) and influencing ESCC outcomes remains unclear.
We integrated single-cell RNA sequencing, TCR sequencing, microarray, and bulk RNA sequencing to dissect Tex cells.
We identified a novel proliferative Tex (prolif Tex) subset across discovery and validation cohorts, with high infiltration correlating significantly with an improved patient survival. Pseudotime trajectories suggested prolif Tex originated from Tex cells, while TCR sequencing revealed clonal expansion and shared receptor repertoires between Tex and prolif Tex.
Neoadjuvant chemo-immunotherapy reduced prolif Tex proportions and differentiation potential in ESCC samples. A machine learning-derived prognostic model was developed using prolif Tex subset-specific genes and validated via qRT-PCR using in-house ESCC samples. Experimental validation confirmed differential expression of candidate genes in tumors versus normal tissues, with high ESCO2 expression linked to prolonged survival.
Our findings unveil prolif Tex cells as a novel TME subset in ESCC, where its abundance predicts favorable outcomes. The prolif Tex-based prognostic model demonstrates strong prognostic value and validated hub genes offer potential biomarkers and therapeutic targets.
Our findings underscore the potential of prolif Tex cells as a biomarker and therapeutic target in ESCC.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。